Targeting Estrogen Receptor Beta in a Phase II Study of High Dose Estradiol in Metastatic Triple Negative Breast Cancer: A Wisconsin Oncology Network Study

BACKGROUND: Estrogen receptor beta (ERβ) is expressed by 50-80% of triple negative breast cancers (TNBC). Agonism of ERβ has antiproliferative effects in TNBC cells expressing ERβ. This phase II study evaluated single agent high dose estradiol in patients with advanced TNBC. PATIENTS AND METHODS: Ad...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Breast Cancer
Autori principali: Wisinski, Kari B., Xu, Wei, Tevaarwerk, Amye J., Saha, Sandeep, Kim, KyungMann, Traynor, Anne, Dietrich, Leah, Hegeman, Robert, Patel, Dhimant, Blank, Jules, Harter, Josephine, Burkard, Mark E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4969205/
https://ncbi.nlm.nih.gov/pubmed/27133732
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clbc.2016.03.005
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi